Results 61 to 70 of about 31,435 (210)

Dehydroepiandrosterone sulfate (DHEAS) is neuroprotective when administered either before or after injury in a focal cortical cold lesion model [PDF]

, 2006
Dehydroepiandrosterone and its sulfate (DHEAS) are sex hormone precursors that exert marked neurotrophic and/or neuroprotective activity in the central nervous system.
Dobszay B., Gábor, Farkas, Tamás, Juhász-Vedres, Gabriella, Kis, Zsolt, Párducz, Árpád, Rákos, Gabriella, Rózsa, Éva, Toldi, József, Wölfling, János   +8 more
core  

Long‐term benefit from adjuvant tamoxifen therapy for ER+ HER2− breast cancer by PR positivity

International Journal of Cancer, EarlyView.
What's New? Tamoxifen is a cornerstone of endocrine therapy for estrogen receptor (ER)‐positive/human epidermal growth factor receptor 2 (HER2)‐negative breast cancer. Its long‐term benefits, however, may vary by progesterone receptor (PR) status. Here, using data from the Stockholm tamoxifen trials, the authors evaluated whether PR expression predicts
Anna E. Nordenskjöld, Magdalena Ríos‐Romero, Huma Dar, Tommy Fornander, Gizeh Perez‐Tenorio, Helena Fohlin, Olle Stål, Julia Tutzauer, Linda S. Lindström   +8 more
wiley   +1 more source

Pregnancy And Neonatal Outcomes Of hMG Stimulation With Or Without Letrozole In Endometrial Preparation For Frozen–Thawed Embryo Transfer In Ovulatory Women: A Large Retrospective Cohort Study

Drug Design, Development and Therapy, 2019
Jiaying Lin,* Ningling Wang,* Jialv Huang, Renfei Cai, Yong Fan, Yanping Kuang, Yun Wang Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of ...
Lin J, Wang N, Huang J, Cai R, Fan Y, Kuang Y, Wang Y   +6 more
doaj  

Trastuzumab (Herceptin (R)): Monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation [PDF]

, 2006
Trastuzumab (Herceptin (R)) is a humanized monoclonal antibody that specifically targets HER2/neu (human epidermal growth factor receptor-2) breast cancer cells, which are overexpressed in about 25-30% of breast carcinomas.
Bauerfeind, Ingo, Ditsch, Nina, Friese, Klaus, Kahlert, Steffen, Kümper, Carolin, Lenhard, Miriam, Rückert, Sandra, Untch, Michael   +7 more
core   +2 more sources

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

The Predictive Value of the Tumor‐Stroma Ratio for Neoadjuvant Endocrine Therapy in Hormone Receptor‐Positive Breast Cancer

International Journal of Cancer, EarlyView.
Neoadjuvant endocrine therapy (NET) can help prevent metastases and improve survival in patients with hormone receptor‐positive (HR+) breast cancer. Identifying which HR+ patients will benefit from NET, however, remains challenging. Here, in a patient cohort in the Netherlands, the authors evaluated tumor‐stroma ratio (TSR) and magnetic resonance ...
Layla Andour, Sophie C. Hagenaars, Anne Florine de Groot, Elly M. M. Krol‐Warmerdam, Judith R. Kroep, Hans Marten Hazelbag, Gerrit‐Jan Liefers, Marieke E. Straver, Wilma E. Mesker   +8 more
wiley   +1 more source

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers [PDF]

, 2013
Introduction: We examined if a combination of proliferation markers and estrogen receptor (ER) activity could predict early versus late relapses in ER-positive breast cancer and inform the choice and length of adjuvant endocrine therapy.
Achim Rody, AJ Minn, Angelica Fasolo, B Haibe-Kains, B Thurlimann, Benjamin Haibe-Kains, C Bellera, C Davies, C Desmedt, C Kim, C Sotiriou, Catherine M Kelly, Christos Sotiriou, CJ van de Velde, D Sgroi, E Amir, G Bianchini, G Bianchini, G Tang, Giampaolo Bianchini, Gianluca Del Conte, H Jin, I Jatoi, JS Parker, KR Hess, KS Albain, Lajos Pusztai, Libero Santarpia, Luca Gianni, M Dowsett, M Filipits, M Schmidt, Marcus Schmidt, Milvia Zambetti, MJ Ellis, MJ van de Vijver, MM Regan, P Dubsky, R Simon, S Loi, S Loi, S Paik, Sven Becker, Takayuki Iwamoto, Thomas Karn, TO Nielsen, Uwe Holtrich, Volkmar Müller, W Fraser Symmans, WF Symmans, WR Miller, Y Wang, Y Zhang, Yuan Qi   +53 more
core   +1 more source

Optimizing outcomes in intrauterine insemination: A narrative synthesis of two decades of clinical research (2000–2024)

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Intrauterine insemination (IUI) is a widely used first‐line fertility treatment, yet its success rates vary considerably. This review synthesizes evidence from peer‐reviewed studies published between 2000 and 2024, including randomized controlled trials, cohort and case–control studies, as well as systematic and narrative reviews identified ...
Kasuni Akalanka
wiley   +1 more source

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer [PDF]

, 2012
PMCID: PMC3446380This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided ...
A Borg, AC Wolff, Adrian Harris, C Wright, DA Budwit-Novotny, DJ Slamon, DJ Slamon, E Tagliabue, EA Musgrove, EHR Perez, G Arpino, G Konecny, GD Lewis Phillips, Georges Sumo, IL Andrulis, Isabel Pinhel, Ivana Sestak, J Cuzick, J Vandesompele, JA Sparano, Jack Cuzick, Janine Salter, JC Brase, JM Harvey, Judith M Bliss, M Dowsett, M Dowsett, M Harigopal, Margaret Hills, ME Hammond, MF Press, Mitch Dowsett, MJ Ellis, MJ Ellis, MJ Piccart-Gebhart, N Quenel, P Royston, Peter Barrett-Lee, RL Camp, Roger A'Hern, S Drury, S Johnston, S Paik, SJ Houston, SS Badve, Suzanne Drury, The Adjuvant Breast Cancer Trials Collaborative Group, V Guarneri, VS Perez   +48 more
core   +5 more sources

Luteal phase stimulation versus follicular phase stimulation in poor ovarian responders: A systematic review and a meta‐analysis

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Background Poor ovarian response (POR) complicates a substantial proportion of in vitro fertilization (IVF) cycles, frequently causing cycle cancellation and suboptimal reproductive outcomes. Conventional follicular‐phase ovarian stimulation (FPOS) protocols often yield limited results, prompting the evaluation of alternative strategies such ...
Vittorio Agrifoglio, Antonio D'Amato, Mariano Catello Di Donna, Marika Marino, Antonio Simone Laganà, Renato Venezia, Davide Vinci, Gaetano Riemma, Andrea Etrusco   +8 more
wiley   +1 more source